Medigen Biotechnology Corp is a biotech company in Asia. The company focuses on the clinical stage of drug development and commercialization of technologies, with a portfolio of products approved by regulatory bodies in various countries. Medigen operates in the vaccine biopharmaceuticals industry and has subsidiaries such as Medigen Vaccine Biologics Corporation and TBG Diagnostics Limited. The company utilizes GTP certificated cell processing facility and is involved in cell therapy cooperation and regulation. Medigen's products include NK CELL (MAGICELL-NK) and OBP-301 (Telomelysin), and it is engaged in COVID-19 clinical trials. The company aims to become a multinational biomedical group through expansion into new businesses and mergers and acquisitions.
Headquarters
14F.,Bldg.F,No.3,Yuancyu St, Nangang District
Taipei City; Taipei City;
Contact Details: Purchase the Medigen Biotechnology Corporation (基亚生物科技股份有限公司) report to view the information.
Website: http://www.medigen.com.tw
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service